Brokers Watch List: Mylan N.V. (NASDAQ:MYL), Synchrony Financial (NYSE:SYF)

nyse

Mylan N.V. (NASDAQ:MYL)

The company announced its last quarter financial performance results on 11/09/2016. Mylan N.V. (NASDAQ:MYL) belongs to Medical sector that surged 0.46% in value when last trading session closed at $37.38. The company has a market capitalization of $19.9 Billion. The company’s stock has a Return on Assets (ROA) of 0.9 percent, a Return on Equity (ROE) of 2.4 percent and Return on Investment (ROI) of 8.2 percent. The company reached its 52-Week high of $54.44 on Jan 6, 2016 and 52-Week low of $33.6 on Nov 3, 2016.

Earnings per share (ttm) for Mylan N.V. (NASDAQ:MYL) according to Finviz Data is $0.51.

The growth estimate for Mylan N.V. (NASDAQ:MYL) for the current quarter is 17.2 percent. The projected growth estimate for the next quarter is 30.3 percent. The company’s stock has grown by 17.82 percent in the past 5 years. For the next 5 years, the company is expected to grow by 9.04 percent.

This company was Initiated by Mizuho on 26-Oct-16  to Buy.

The 18 analysts offering 12-month price forecasts for Mylan NV have a median target of 52.00, with a high estimate of 59.00 and a low estimate of 43.00. The median estimate represents a +39.11% increase from the last price of 37.38.

Financial History:

Following Earnings result, share price were UP 14 times out of last 27 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 66% percent of times. It has met expectations  1 times and missed earnings  3  times.

The consensus recommendation for Mylan N.V. (NASDAQ:MYL) is 1.83. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.83. In comparison, the consensus recommendation 60 days ago was at 1.83, and 90 days ago was at 2.2 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Mylan N.V. to have earnings per share of $1.43.

Revenue is expected to range from 3.1 Billion to 3.27 Billion with an average of 3.19 Billion.

Company Profile:

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.

Synchrony Financial (NYSE:SYF):

Synchrony Financial (NYSE:SYF) belongs to Finance sector closed its last session with a loss of -0.41 percent and closed its previous trading session at $36.09. According to Finviz reported data, the stock currently has Earnings per Share (EPS) (ttm) of $2.66. The company has the Market capitalization of $29.88 Billion. The company’s stock has a Return on Assets (ROA) of 2.7 percent, a Return on Equity (ROE) of 16.6 percent and Return on Investment (ROI) of 21.2 percent. The company reached its 52-Week high of $37.31 on Dec 21, 2016 and 52-Week low of $23.25 on Jun 27, 2016.

This company was Upgrade by BofA/Merrill on 15-Dec-16 to Buy.

The 22 analysts offering 12-month price forecasts for Synchrony Financial have a median target of 40.00, with a high estimate of 43.00 and a low estimate of 30.00. The median estimate represents a +10.83% increase from the last price of 36.09.

Financial History:

Following Earnings result, share price were UP 5 times out of last 8 Qtrs. In the last 27 earnings reports, the company has topped earnings-per-share estimates 100% percent of times. It has met expectations  0 times and missed earnings  0 times.

The consensus recommendation for Synchrony Financial (NYSE:SYF) is 1.33. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. The consensus recommendation 30 days ago for this company stood at 1.33. In comparison, the consensus recommendation 60 days ago was at 1.36, and 90 days ago was at 1.4 respectively.

Future Expectations:

When the current quarter ends, Wall Street expects Synchrony Financial to have earnings per share of $0.67.

Revenue is expected to range from 3.48 Billion to 3.65 Billion with an average of 3.56 Billion.

Company Profile:

Synchrony Financial is a consumer financial services company. It offers private label credit cards, dual cards and small and medium-sized business credit products; promotional financing for consumer purchases, including installment loans; and promotional financing to consumers. The company also offers various deposit products, such as certificates of deposit, individual retirement accounts, money market accounts, and savings accounts directly to retail and commercial customers under the Optimizer+Plus brand. Synchrony Financial is headquartered in Stamford, Connecticut.